Antibodies specific to delta 1 chain of T cell receptor
AssigneeNew York University
InventorsShohei Koide, George Miller, Akiko Koide, Tatyana Panchenko
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antibodies specific to a delta1 chain of a γδ T cell receptor and methods of using such for modulating γδ T cell bioactivity. Such anti-Delta1 antibodies may also be used to treat diseases associated with γδ T cell activation, such as solid tumors, or for detecting presence of γδ1 T cells.
Claims19
A method of inhibiting the activation of immunosuppressive γδ T cells in a subject, the method comprising administering to a subject having or suspected of having a solid cancer a pharmaceutical composition comprising an antibody that binds a delta 1 chain of a T cell receptor, wherein the pharmaceutical composition is administered to the subject in an amount effective to enhance an anti-tumor immune response, and wherein the antibody comprises:
- a heavy chain comprising a heavy chain variable region (VH), wherein the VH comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 43, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 57, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 77 and
- a light chain comprising a light chain variable region (VL), wherein the VL comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 46, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 47, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 78.
A method of treating a solid tumor, the method comprising administering to a subject having or suspected of having a solid tumor an effective amount of a pharmaceutical composition comprising an antibody that binds a delta 1 chain of a T cell receptor to enhance anti-tumor immune responses, wherein the antibody comprises
- a heavy chain comprising a heavy chain variable region (VH), wherein the VH comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 43, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 57, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 77 and
- a light chain comprising a light chain variable region (VL), wherein the VL comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 46, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 47, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 78.
Dependencies are inferred from the claim text.